The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
The global payments giant reported a 15% surge in net revenue and processed a record 69.4 billion transactions in its fiscal first quarter, signaling resilient consumer confidence and a rebound from previous quarters.
Former President Donald Trump has announced Kevin Warsh, a former Federal Reserve governor and economic advisor, as his pick to lead the central bank. The nomination comes as incumbent Chair Jerome Powell faces a federal investigation related to his congressional testimony.
A Dominus and Cheyne Capital partnership wins City of London approval to convert the Grade II-listed Ibex House into a 382-room hotel, slated for a late 2028 opening, complete with a hospitality academy and restored pub.
Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
In the shadow of tech giants, two quantum computing specialists, IonQ and D-Wave Quantum, are vying for investor attention with distinct approaches to AI. While both remain speculative bets, a closer look at their technology, finances, and market position reveals one as a potentially less volatile choice for those venturing into this frontier.
Amid a mixed market landscape, corporate insiders are placing significant bets on select small-cap stocks. We analyze three companies where recent insider buying and strategic moves signal potential value, despite broader economic headwinds.
Amidst a mixed economic backdrop, we spotlight three U.S. tech companies—Rumble, Daktronics, and Sandisk—whose strategic initiatives and robust growth projections set them apart for investors looking beyond near-term turbulence.
Rising global defense budgets are accelerating the adoption of artificial intelligence in military systems, with companies racing to develop advanced sensing and threat-detection capabilities through strategic partnerships and acquisitions.
As markets navigate a volatile start to 2026, income-focused investors are turning to dividend payers for resilience. We analyze three companies with strong cash flows and shareholder return commitments.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
The ninth edition of the Istanbul Fashion Connection (IFCO) is poised to gather an estimated 30,000 trade visitors and 400 exhibitors this February, highlighting Turkey's expanding influence in the global apparel sourcing landscape.
Alphabet's self-driving unit Waymo is in advanced talks to secure a massive $16 billion funding round, potentially valuing the company at around $110 billion, as competition in the robotaxi market intensifies.
A hefty cash reserve is typically a corporate strength, but for some companies, it signals stagnation rather than security. We examine three firms—Box, C3.ai, and Novavax—where significant net cash positions fail to offset concerns over growth prospects and valuation.
While small-cap stocks offer potential for high returns ahead of Wall Street coverage, their lack of scale compared to larger rivals introduces significant risk. We analyze one contender with strong prospects and two that may disappoint.
The industrial sector has been a quiet powerhouse, outpacing the broader market. Yet, amid the rally, some prominent names carry significant risks that warrant a closer look from investors.
